This assay complements the standard KRAS Mutation Analysis of exons 2 and 3. Mutations in exon 4 are detected in approximately 1-4% of colorectal cancers. Exon 4 analysis is appropriate for detecting activating mutations that may confer resistance to EGFR-targeted inhibitors and predicts sensitivity to MEK inhibition.